Rare diseases: Opportunistic or Philanthropic?
This article was originally published in Scrip
With special incentives associated with orphan drug status and the technological advances underpinned by better understanding of the underlying genetics, it is not surprising that rare diseases have become an increasingly attractive target for the pharma and biotech companies. However, while most companies' entry into the orphan drug field has been primarily motivated by the potential for technology breakthroughs and the business opportunity, the societal impact is also a potential major driver.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.